Solid Biosciences Inc (SLDB)

08:28 AM

We Think Solid Biosciences (NASDAQ:SLDB) Can Afford To Drive Business Growth - Yahoo Finance

08:28 AM

May 16, 2025

SLDB: Piper Sandler Lowers Price Target for Solid Biosciences | SLDB Stock News - GuruFocus

May 16, 2025

May 16, 2025

Truist maintains buy on Solid Biosciences stock, price target at $16 - Investing.com

May 16, 2025

May 16, 2025

Solid Biosciences (SLDB) Maintains Overweight Rating Amid Price Target Adjustment | SLDB Stock News - GuruFocus

May 16, 2025

May 16, 2025

Solid Biosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 16, 2025

May 16, 2025

Solid Biosciences (SLDB) Target Price Revised Amid Share Count Changes | SLDB Stock News - GuruFocus

May 16, 2025

May 16, 2025

Wedbush Cuts Price Target on Solid Biosciences to $17 From $18, Keeps Outperform Rating - marketscreener.com

May 16, 2025

May 16, 2025

Solid Biosciences (SLDB) Sees Price Target Cut by Piper Sandler Amid Trial Updates | SLDB Stock News - GuruFocus

May 16, 2025

May 16, 2025

Solid Biosciences: Promising Gene Therapy Advancements and Strategic Initiatives Drive Buy Rating - TipRanks

May 16, 2025

May 16, 2025

Barclays Adjusts Price Target for Solid Biosciences (SLDB) Amid Progress | SLDB Stock News - GuruFocus

May 16, 2025

May 15, 2025

Solid Biosciences Files $400 Million Mixed Shelf - marketscreener.com

May 15, 2025

May 15, 2025

Solid Biosciences Files Prospectus for $85 Million Offering - TipRanks

May 15, 2025

May 15, 2025

SLDB Shows Promise with Early Results in Duchenne Muscular Dystrophy Trial | SLDB Stock News - GuruFocus

May 15, 2025

May 15, 2025

Solid Biosciences (SLDB) Files for $400 Million Mixed Securities Shelf | SLDB Stock News - GuruFocus

May 15, 2025

May 15, 2025

Solid Biosciences Inc Files For Mixed Shelf Of Up To $400 Million - marketscreener.com

May 15, 2025

May 15, 2025

Form 424B5 Solid Biosciences Inc. - StreetInsider

May 15, 2025

May 15, 2025

Solid Biosciences Reports First Quarter 2025 Financial Results a - GuruFocus

May 15, 2025

May 15, 2025

Solid Biosciences Reports First Quarter 2025 Financial Results and Provides Business Updates - GlobeNewswire

May 15, 2025

May 13, 2025

Partner With Us - Solid Biosciences

May 13, 2025

May 01, 2025

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

May 01, 2025

May 01, 2025

Solid Biosciences Expands Team: 81,000 RSUs Awarded to 7 Strategic New Hires - Stock Titan

May 01, 2025

Apr 30, 2025

Solid Biosciences to Participate at The Citizens Life Sciences Conference - The Manila Times

Apr 30, 2025

Apr 30, 2025

Exclusive: Solid Biosciences CEO Ready to Reveal Latest Company Vision at Major Life Sciences Event - Stock Titan

Apr 30, 2025

Apr 29, 2025

Solid Biosciences to Present at the American Society of Gene and Cell Therapy's 28th Annual Meeting - The Manila Times

Apr 29, 2025

Apr 29, 2025

Solid Biosciences to Present Phase 1/2 Trial Data for SGT-003 Gene Therapy at ASGCT 2025 Annual Meeting - Nasdaq

Apr 29, 2025

Apr 29, 2025

Solid Biosciences to Present at the American Society of Gene and Cell Therapy’s 28th Annual Meeting - GlobeNewswire

Apr 29, 2025

Apr 29, 2025

New Duchenne Treatment Breakthrough: Solid Bio Unveils Critical Gene Therapy Trial Results at Major Conference - Stock Titan

Apr 29, 2025

Apr 28, 2025

Montai Therapeutics Appoints Allison Bogosian, JD, as Chief People and Administrative Officer - Business Wire

Apr 28, 2025

Apr 21, 2025

Piper Sandler Remains a Buy on Solid Biosciences (SLDB) - The Globe and Mail

Apr 21, 2025

Apr 19, 2025

Certain Restricted Stock Units of Solid Biosciences Inc. are subject to a Lock-Up Agreement Ending on 20-APR-2025. - marketscreener.com

Apr 19, 2025

Apr 19, 2025

Certain Common Stock of Solid Biosciences Inc. are subject to a Lock-Up Agreement Ending on 20-APR-2025. - marketscreener.com

Apr 19, 2025

Apr 16, 2025

Solid Biosciences stock hits 52-week low at $2.47 By Investing.com - Investing.com South Africa

Apr 16, 2025

Apr 16, 2025

Solid Biosciences stock hits 52-week low at $2.47 - Investing.com Australia

Apr 16, 2025

Apr 13, 2025

Can Solid Biosciences Challenge Sarepta in the DMD Market? - MSN

Apr 13, 2025

Apr 08, 2025

Solid Biosciences: A Strong Buy As An Emerging Biotech In The Gene Therapy Space - Seeking Alpha

Apr 08, 2025

Apr 07, 2025

Solid Biosciences stock hits 52-week low at $2.88 - Investing.com Australia

Apr 07, 2025

Apr 07, 2025

Solid Biosciences stock hits 52-week low at $2.88 By Investing.com - Investing.com South Africa

Apr 07, 2025

Apr 07, 2025

Solid Biosciences to Participate at Upcoming Investor Conferences - GlobeNewswire

Apr 07, 2025

Apr 07, 2025

Exclusive Access: Solid Biosciences Leadership Team Headlines Two Major Healthcare Conferences - Stock Titan

Apr 07, 2025

Apr 01, 2025

Solid Biosciences reports inducement grants under Nasdaq listing rule - TipRanks

Apr 01, 2025

Apr 01, 2025

Solid Biosciences Expands Team with 43,374 RSU Grants in Strategic Hiring Move - Stock Titan

Apr 01, 2025

Mar 20, 2025

Sarepta safety update on Elevidys boosts Regenxbio, hurts Solid Bio - MSN

Mar 20, 2025

Mar 20, 2025

Truist Financial Keeps Their Buy Rating on Solid Biosciences (SLDB) - The Globe and Mail

Mar 20, 2025

Mar 19, 2025

Solid Biosciences Inc.'s (NASDAQ:SLDB) market cap dropped US$53m last week; Private equity firms bore the brunt - simplywall.st

Mar 19, 2025

Mar 18, 2025

Regenxbio stock up, Solid Bio down post Sarepta update (RGNX) - Seeking Alpha

Mar 18, 2025

Mar 14, 2025

Solid Biosciences Inc. (SLDB): Among Top Insider Purchases Last Month - Insider Monkey

Mar 14, 2025

Mar 13, 2025

Solid Biosciences director Kahn Clare buys $9,924 in stock - Investing.com India

Mar 13, 2025